ABSTRACT: Chemotherapy-related cardiac dysfunction is a significant side effect of anticancer treatment. Risk stratification is based on clinical-and treatment-related risk factors that do not adequately explain individual susceptibility. The addition of genetic variants may improve risk assessment. We conducted a systematic literature search in PubMed and Embase, to identify studies investigating genetic risk factors for chemotherapy-related cardiac dysfunction. Included were articles describing genetic variants in humans altering susceptibility to chemotherapy-related cardiac dysfunction. The validity of identified studies was assessed by 10 criteria, including assessment of population stratification, statistical methodology, and replication of findings. We identified 40 studies: 34 exploring genetic risk factors for anthracyclineinduced cardiotoxicity (n=9678) and 6 studies related to trastuzumabassociated cardiotoxicity (n=642). The majority (35/40) of studies had a candidate gene approach, whereas 5 genome-wide association studies have been performed. We identified 25 genetic variants in 20 genes and 2 intergenic variants reported significant at least once. The overall validity of studies was limited, with small cohorts, failure to assess population ancestry and lack of replication. SNPs with the most robust evidence up to this point are CELF4 rs1786814 (sarcomere structure and function), RARG rs2229774 (topoisomerase-2β expression), SLC28A3 rs7853758 (drug transport), UGT1A6 rs17863783 (drug metabolism), and 1 intergenic variant (rs28714259). Existing evidence supports the hypothesis that genetic variation contributes to chemotherapy-related cardiac dysfunction. Although many variants identified by this systematic review show potential to improve risk stratification, future studies are necessary for validation and assessment of their value in a diagnostic and prognostic setting.
C hemotherapy-related cardiac dysfunction (CTRCD) is a notorious side effect of various chemotherapeutic agents. Traditionally, 2 types of cardiotoxicity are distinguished based on the induced effect of the agent on the heart. 1 Anthracyclines, for example, doxorubicin, are most well known for their association with type I cardiotoxicity and frequently administered in various malignancies. Type I cardiotoxicity is characterized by direct irreversible damage and is dose related. Regardless of restrictions in the maximum cumulative dose, 1 infusion rate, 2 and alternative drug formulations 3 to diminish cardiac damage, the incidence of anthracycline-induced cardiotoxicity (AIC) is still 9% to 18%. 4, 5 With a 60% mortality rate at 2 years in symptomatic heart failure patients, the prognosis is strikingly poor. 6 The outcome of type II cardiotoxicity is generally more favorable as it often is reversible and independent of the administered dose. 7 Trastuzumab, one of the main agents associated with type II cardiotoxicity, is predominantly used to treat women with HER2 (human epidermal growth factor receptor-2)-positive breast cancer constituting ≈20% of all breast cancer patients. Cardiotoxicity develops in 7.1% to 18.6% of these patients and increases even further in treatment regimens that additionally contain anthracyclines. 8 Albeit the subdivision into type I and II cardiotoxicity is arbitrary, as persistent LV dysfunction has been observed in some patients treated solely with agents associated with type II cardiotoxicity, 9 these subclasses are still widely applied.
For both types of CTRCD, known clinical risk factors do not adequately explain individual risk, suggesting the presence of other determinants. 10 The use of pharmacogenomics, the scientific field that aims to individualize therapy and improve patient outcome by using genomic information, may enhance CTRCD risk stratification. Genetic markers with the potential to predict whether a patient will develop CTRCD can allow for the identification of patients who will benefit from careful monitoring, prescription of cardioprotective drugs, and enable early treatment initiation once CTRCD has developed. This systematic review provides a comprehensive overview of all genetic variants that have been implicated to influence susceptibility to CTRCD. Furthermore, identified variants are discussed in the light of current theories on the complex pathophysiological mechanisms responsible for this adverse drug reaction.
METHODS
The authors declare that all supporting data are available within the article and in the Data Supplement.
We searched PubMed and Embase for articles exploring genetic risk factors for cardiotoxicity in oncology patients treated with chemotherapy. Our search syntax (Table I in the Data Supplement) included a combination of the following terms: gene, pharmacogene, mutation, variant, single nucleotide polymorphism, chemotherapy, anthracyclines, trastuzumab, cardiotoxicity, and heart failure. The systematic search was performed on June 15, 2017, by one author (M.L.). No restriction was used on publication date. Main inclusion criteria were original articles investigating genetic variants in humans that might modulate susceptibility to CTRCD, and articles written in English. No criteria were used for the definition of CTRCD, as multiple definitions have been proposed and to date no consensus has been reached. 11 In this review, we have chosen to use the outcome definition of CTRCD as an umbrella term for all different definitions of cardiotoxicity applied across studies, including a decline in left ventricular ejection fraction or signs/symptoms of heart failure. Furthermore, we included patients of all ages. Excluded were articles describing genetic alterations in animal models, in vitro experiments, expression profiling studies, and review articles.
Further filtering of articles was performed based on fulltext assessment in case title and abstract were considered relevant. Absence of full-text availability ( Figure I in the Data Supplement), case reports, and conference abstracts were considered additional exclusion criteria. For articles that met our inclusion criteria, we screened listed references to identify publications that were not identified with our search string.
Identified variants were subsequently subdivided into different groups based on possible pathophysiological mechanisms of CTRCD that have been described in literature.
The validity of identified studies was assessed on the basis of 10 criteria: potential selection bias, phenotype definition and recording, assessment of population stratification and HardyWeinberg equilibrium, blinding of genotype to outcome, accuracy of genotyping measurements, statistical methodology, replication of data in an independent cohort, consistency of results in comparison with other studies, and functional follow-up. Per criterium that was met, one point was given and the overall scores were subsequently subdivided into 5 different categories (A-E), where A represents a study that fulfilled (almost) all criteria and E studies that failed to do so.
RESULTS
In total, 1213 articles were screened for eligibility on the basis of title and abstract ( Figure I in the Data Supplement). After applying inclusion and exclusion criteria, 40 articles were selected for inclusion, 34 studies investigated genetic risk factors for AIC (n=9678 patients, 69,8% female) and 6 studies involved trastuzumab (n=642 patients). The majority (35/40) were candidate gene studies, whereas 5 genome-wide association studies (GWASs) have been performed. Twenty-six of 40 cohorts were composed of adults, 11 of 40 of children or childhood cancer survivors, and 3 of 40 studies included all ages. We identified 25 genetic variants in 20 genes and 2 intergenic variants that have been associated with CTRCD at least once (Table) and subdivided these variants according to the potential pathophysiological mechanisms. With some 
Anthracycline-Induced Cardiotoxicity
An overview of studies exploring genetic risk factors for AIC is provided in Table II in the Data Supplement. A model of the proposed pathogenesis of AIC in combination with the genes that up to this point have been associated with AIC is depicted in Figure 1 .
Generation of Excess Reactive Oxygen Species
The generation of excess reactive oxygen species (ROS) is the most widespread theory of mechanisms that mediate AIC. 47 Because of low levels of enzymes that neutralize these species in cardiac tissue (eg, catalase and superoxide dismutase), the heart is especially prone to oxidative stress. 48 ROS interact with and thereby damage DNA, proteins, and lipid membranes.
ROS are among other generated by the repetitive coupling of reduction and oxidation reactions between the semiquinone and quinone forms of anthracyclines. 49 The semiquinone radical is generated by a one electron reduction of the quinone moiety, which thereafter 
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transfers its unpaired electron to oxygen. This generates superoxide and hydrogen peroxide and the conversion of the semiquinone moiety back to a quinone structure.
Reduction of the semiquinone moiety can be catalyzed by cytochrome P450 oxidoreductase and nitric oxide synthase 3 (encoded by POR and NOS3), and genetic variants in these genes have been reported to associate with AIC. 24, 36 Nevertheless, only variants in POR have been replicated in a recent GWAS with a nominal P value <0.05. 13 Another enzyme complex thought to be an important source of ROS in cardiac tissue is NADPH oxidase The genes presented in this systematic review support 4 main pathophysiological mechanisms that mediate AIC namely (1) generation of excess reactive oxygen species (ROS), (2) accumulation of cardiotoxic metabolites, (3) interaction of anthracyclines with topoisomerase-2β TOP-2ß, and (4) disruption of sarcomere structure and function. The cardiotoxic effects of anthracyclines are in addition aggravated by iron on multiple levels namely the disruption of iron metabolism that causes iron accumulation, increased oxidative stress, and the generation of anthracycline-iron complexes that cause lipid membrane peroxidation.
(encoded by among others NCF4, RAC2, and CYBA). Wojnowski et al 17 identified variants in CYBA (rs4673), NCF4 (rs1883112), and RAC2 (rs13058338) to be associated with AIC and subsequently confirmed this association in an animal study. A mice model with a decreased NADPH oxidase activity did not develop cardiotoxicity after intraperitoneal doxorubicin injections in contrast to the wild-type mice. 17 Furthermore, in heart tissue isolated from patients exposed to anthracyclines, NCF4 (rs1883112) was demonstrated to be highly associated with interstitial fibrosis and CYBA (rs4673) with patched myocardial necrosis. Carriers of the high-risk allele showed these lesions to a greater extent. 20 Additional evidence for the role of NADPH oxidase in AIC came with 2 other studies that replicated the association between polymorphisms in NCF4 and RAC2 and CTRCD. 19, 21 Nonetheless, multiple other studies have not reported an association, likely related to the large heterogeneity among these studies with regards to age, ancestry, and case definition (Table II in the Data Supplement), making mutual comparisons impracticable. [13] [14] [15] [16] 18, 19, 21, 22, 28 The effects of ROS are thought to be aggravated by iron, for which anthracyclines have a high affinity. 47 Iron-anthracycline complexes can cause lipid peroxidation and superoxide, and hydrogen peroxide can be transformed to even more reactive species in the presence of iron. 47, 49 In addition, anthracyclines disrupt iron metabolism which causes the accumulation of iron in cardiomyocytes, further potentiating cardiotoxic anthracycline effects. 50 Iron storage diseases (eg, hemochromatosis) may, therefore, increase the risk of AIC. 38, 39 Cascales et al 38 investigated necropsy heart tissue from patients who underwent anthracycline therapy in the context of various solid and hematological malignancies and found an increase in myocardial iron in patients treated with a cumulative doxorubicin dose >200 mg/m 2 . Furthermore, there was a greater degree of cardiac iron deposits in patients with hemochromatosis mutated haplotypes. Studies investigating an association between 2 common hemochromatosis causing variants in the HFE gene (C282Y rs1799945 and H63D rs1800562) and CTRCD have, however, shown conflicting results. 13, 19, 22, 38, 39 It should be noted that the overall sample size of these studies was small, and the impact of hemochromatosis on CTRCD risk, therefore, remains inconclusive.
Last, various proteins that increase the resistance of cardiomyocytes to ROS, including the antioxidants catalase (CAT rs10836235), glutathione S-transferase π-1 (GSTP1 rs1695), and a protein involved in DNA repair (ERCC2 rs13181), have been studied in various cohorts. 13, 14, 21, 22, [27] [28] [29] [30] 37 To date, these SNPs are supported by limited evidence. A notable exception is a polymorphism in HAS3 (rs223228) encoding hyaluronic acid, which is an abundant protein in the extracellular matrix. 23 Wang et al 23 found and replicated a dose-dependent association of rs223228 with AIC. In a functional followup experiment, HAS3 mRNA levels in healthy heart tissue of individuals homozygous for the high-risk allele were decreased when compared with heterozygous carriers. 23 As hyaluronic acid has antioxidant activity, decreased expression could result in a decline of cardiac antioxidant capacity and thereby an increased risk of AIC.
Intracellular Accumulation of Cardiotoxic Metabolites
Genetic variants leading to differences in efficacy of enzymes and transporters that might alter pharmacokinetics have also been investigated for a role in cardiotoxicity.
Anthracyclines are metabolized to alcohol metabolites (eg, doxorubicin to doxorubicinol) which because of their polarity accumulate intracellularly and are thought to be important mediators of AIC. 51, 52 Differences in the rate of conversion of anthracyclines to these metabolites or their transport out of the cell may, therefore, contribute to differential AIC risk.
Polymorphisms in enzymes that catalyze the reaction of anthracyclines to alcohol metabolites, for example, carbonyl reductases (CBR1 and CBR3) have been extensively studied. 13, 14, 19, 22, 28, 29, [31] [32] [33] [34] [35] However, only rs1056892 in CBR3 has been significantly associated with CTRCD and validated in a GWAS (P=0.03). 31, 32 In a pharmacokinetic experiment, this polymorphism was shown to alter the rate of conversion to doxorubicinol, where the high-risk allele caused a 2.6-fold increase in conversion, possibly leading to higher levels of cardiotoxic alcohol metabolites. 33 A variant in UGT1A6 (rs17863783) is suspected to mediate cardiotoxicity in a similar manner. This gene encodes for a Uridine 5'-diphospho-(UDP) glucuronosyltransferase that adds a glucuronic acid moiety to a variety of substrates and plays a major role of the elimination of various drugs. Enzyme activity is altered in the presence of a haplotype that is tagged by this SNP. 53 The role of the glucuronidation reaction in the elimination of anthracyclines and its metabolites is unclear.
14 Nonetheless, because this variant has been replicated across various studies, 14, 22, 25 a role for this enzyme in the elimination of cardiotoxic anthracycline metabolites is conceivable.
Last, variants in genes encoding for membrane transporters that regulate anthracycline influx (SLC28A3) and efflux (ABCC1, ABCC2, ABCC5) have been found to associate with AIC in several studies. [12] [13] [14] 16, 17, 19, 24, 25 SLC28A3 is supported by the most extensive evidence, with a polymorphism (rs7853758) in which the minor allele has proven to have a protective effect in 3 pediatric cohorts. 14, 25 Carriers of the high-risk allele have a reduced expression of SLC28A3 mRNA in monocytes, which supports the hypothesis that less anthracycline influx in cardiomyocytes results in less cardiotoxicity. 54 
Interaction of Anthracyclines With Topoisomerase-2β
A recently discovered mechanism important in mediating AIC is the interaction of doxorubicin (one of the most used anthracyclines) with topoisomerase-2β in cardiac tissue. 55 Topoisomerase enzymes are important in the untangling of DNA during replication. One of the main antineoplastic effects of doxorubicin involves its interaction with topoisomerase-2α and DNA, leading to topoisomerase-doxorubicin-DNA cleavage complexes that induce cell death. 56 However, in cardiomyocytes, the interaction of doxorubicin with topoisomerase-2β leads to cardiomyocyte apoptosis. 55 A cardiac-specific deletion of topoisomerase-2β protects mice against doxorubicin-induced heart failure, suggesting an important role of this interaction in AIC. 55 The reason for this protection is thought to be multifactorial. In mice with intact topoisomerase-2β, the expression of several antioxidative enzymes is reduced after doxorubicin treatment leading to an increase in ROS generation. 55 In addition, the levels of 2 important mitochondrial transcription factors (PGC1α and PGC1β) are decreased, leading to a decline in proteins involved in the mitochondrial electron transport and subsequently mitochondrial dysfunction. 55, 57 The first GWAS performed in patients with AIC further supports the role of the interaction of anthracyclines with topoisomerase-2β. 13 This study identified a highly significant polymorphism rs2229774 in RARG encoding the retinoic acid receptor gamma. This protein is important in the transcriptional regulation of among others topoisomerase-2β. Extensive in vitro follow-up experiments of the high-risk variant were performed to characterize the functional consequences of this allele. 13 In summary, these experiments showed that RARG represses the expression of topoisomerase-2β, and rat cardiomyoblasts carrying the high-risk genotype express higher basal levels of topoisomerase-2β, which might account for the increased CTRCD risk in carriers of this allele.
Disruption of Sarcomere Structure and Function
Endomyocardial biopsies from patients with anthracycline-related cardiotoxicity show a loss and disarray of myofibrils in the sarcomere. 58 Sarcomere disruption is thought to be dependent on Ca 2+ release from the sarcoplasmic reticulum, induced by the binding of anthracyclines and their metabolites to proteins involved in calcium handling. 52, 59 Genetic variation in genes encoding for structural elements of the sarcomere or their transcriptional regulation may, therefore, be involved in AIC.
Wasielewski et al 10 investigated whether a genetic predisposition for dilated cardiomyopathy (DCM) may constitute a risk factor for AIC. Patients with AIC and a positive family history for DCM were screened for pathogenic mutations in 48 genes known to be associated with genetic DCM. They identified 2 patients with pathogenic mutations in MYH7 encoding the sarcomere protein myosin heavy chain-β. Although it is conceivable that individuals with a predisposition for DCM are more susceptible to AIC in view of a second-hit-like phenomenon, this hypothesis has not been investigated in larger cohorts.
In addition, a recent GWAS identified a variant in CELF4 (rs1786814), encoding for CUGBP Elav-Like Family Member 4. 31 This protein is involved in the regulation of mRNA splicing of the cardiac sarcomere protein troponin T2 (TNNT2). Troponin T2 is part of the thin filament and has a pivotal role in the regulation of muscle contraction in response to intracellular Ca 2+ levels. The splicing of troponin can be switched during development, from a fetal to adult TNNT2 isoform. 60 In failing hearts, coexpression of multiple isoforms has been observed. As each isoform has a distinct Ca 2+ sensitivity, the presence multiple isoforms may result in a dissociated Ca 2+ response and, consequently, a decrease in myocardial pumping efficacy. 61, 62 In a functional followup of the CELF4 polymorphism, Wang et al 31 found that carriers of a high-risk allele were more likely to coexpress embryonic and adult TNNT2 isoforms in the heart, similarly as is the case in DCM.
Trastuzumab-Induced Cardiotoxicity

HER2 Signaling in the Heart
The pathophysiological mechanisms that mediate trastuzumab-induced cardiotoxicity are currently not well understood. Trastuzumab binds to HER2, and thereby, downstream associated signaling cascades of this receptor are inhibited. Because a ventricular-restricted deletion of the gene encoding for HER2 (ERBB2) leads to DCM in mice, 63 it is conceivable that the inhibition of these signaling pathways plays a central role in trastuzumab-induced cardiotoxicity. In cardiomyocytes, these pathways are essential for the stimulation of cardioprotective mechanisms that mediate cardiomyocyte hypertrophy, increase resistance to apoptosis, cell-tocell contact, cell elongation, angiogenesis, and sensitivity to inotropic effects of β 1 -adrenergic agonists. 64 Furthermore, HER2 signaling is essential during fetal cardiac development. Knockout of this receptor or its ligand (neuregulin-1) in mice is not compatible with life, because of abnormal ventricular trabeculation. [65] [66] [67] The most extensively studied polymorphism with regards to trastuzumab-induced cardiotoxicity is ERBB2 Ile655Val (rs1136201). Beauclair et al 41 found that the presence of a Val allele was associated with an increased risk of developing cardiotoxicity. In vitro experiments showed an increased effectivity of trastuzumab and consequently increased inhibition of downstream signaling cascades, in the presence of this genotype cor- responding with the observed raised CTRCD risk. This finding has since been validated in 3 other cohorts. [44] [45] [46] However, this SNP was not replicated by Stanton et al 42 and in a recent randomized clinical trial that investigated the effects of candesartan to prevent trastuzumabinduced cardiotoxicity. 43 Instead, these studies both found an association with another variant in ERBB2 (rs1058808). As there was a homogenous allele distribution of rs1136201 among all studies, reasons for the lack of replication of this SNP might be related to the larger sample size of the 2 latter studies or differences in the handled definition of cardiotoxicity. To date, the evidence of these 2 SNPs is comparable, and it is unclear if both contribute similarly to CTRCD risk. An overview of identified studies exploring genetic risk factors of trastuzumab-induced cardiotoxicity is provided in Table III 
DISCUSSION
This systematic review provides a comprehensive overview of all genetic variants that have been implicated to affect susceptibility to CTRCD. After performing a systematic search in Pubmed and Embase, we identified 25 genetic variants in 20 different genes and 2 intergenic variants that have been associated with CTRCD risk (Table) . The most important findings of our literature review are the following: (1) genetic variations that have been found significant in AIC support the hypothesis that this adverse drug reaction is the final common pathway of multiple pathophysiological mechanisms including the generation of excess ROS, intracellular accumulation of cardiotoxic metabolites, interaction of anthracyclines with topoisomerase-2β, and disruption of sarcomere structure and function; (2) genetic risk factors of trastuzumab-induced cardiotoxicity are largely unexplored; and (3) the overall evidence of the reported variants is limited as the majority lack solid replication and do, therefore, not yet have the potential to improve clinical risk stratification in a diagnostic setting.
We think that there are 3 main reasons for the lack of replication in the identified reports. First, the applied definition of cardiotoxicity varied greatly between studies, from significant ECG abnormalities to various different set thresholds for decrease in ejection fraction (Tables II and III in the Data Supplement) . These differences are likely caused by the lack of consensus on the definition of CTRCD. 11 In addition, studies investigated CTRCD of different onset (acute, subacute, and chronic), and it is conceivable that distinct pathophysiological mechanisms mediate these forms.
Second, many of the candidate gene studies did not correct for multiple comparisons in contrast to studies examining a larger number of SNPs, likely resulting in a larger number of false-positive finding among candidate gene studies. Third, patient characteristics differed on multiple levels. Many studies have been performed in children, albeit childhood cancer is rare and constitutes <1% of all cancers. However, as the impact of age-and environmental-related factors is reduced in the pediatric population, these studies might potentially be beneficial within field. Another remarkable detail is that many studies failed to adequately correct for population stratification and that a majority have been performed in white patients, whereas black race is considered a risk factor for CTRCD. 68 This limited ethnic diversity has previously been recognized an important limitation in genetic research. 69 Moreover, the type of malignancies varied, as well as the type of anthracyclines administered and their dosing. The impact of the various different anthracyclines on the development of cardiotoxicity is currently underexposed in the literature, and studies comparing their efficacy and safety are scarce. 70 It is also plausible that the genetic susceptibility to CTRCD is dependent on the type and dosing of the anthracycline that is administered and that this has contributed considerably to failure of replication. Because of this overall lack of uniformity between identified studies, we chose to not perform a meta-analysis of the genetic variants presented in the Table. The limited yield of the performed candidate gene studies identified with this review suggests that this methodology, which is dependent on a priori biological knowledge, is not well suited for the detection of genetic variants influencing CTRCD susceptibility. Because the pathophysiological mechanisms of CTRCD are not completely elucidated, its phenotype is complex, and most SNPs are likely to have a small to moderate effect size, GWAS might be better suited to further delineate the mechanisms involved. Although large cohorts are generally considered to be necessary for the generation of sufficient statistical power in GWAS, smaller and well-phenotyped cohorts have also proven successful to identify SNPs with moderate effect sizes. 13, 31 The added value of genetic testing in CTRCD risk stratification has been illustrated in 2 cohorts thus far. 14, 19 Receiver operating characteristics analyses in both studies increased the area under the curve from 0.68 to 0.87 and 0.69 to 0.79 when a set of 3 to 9 SNPs were added to a model composed of clinical risk factors only.
Aminkeng et al 70 released the first position article on genetic testing to reduce the incidence of anthracycline-related cardiotoxicity. These recommendations include, among others, genetic testing in all childhood cancer patients treated with doxorubicin or daunorubicin for RARG (rs2229774), SLC28A3 (rs7853758), and UGT1A6 (rs17863783). Aminkeng et al 70 characterize the supporting evidence as "consistent, but limited quantity, quality, or generalizability" where "further research is likely to have an important impact on confidence in conclusions" and the authors call for additional retrospective and prospective studies. The recommendation to genotype the abovementioned SNPs is graded as moderate evidence reflecting a reduced confidence in scientific evidence and expert opinion, and the recommended management options with strong evidence are limited to increased monitoring for cardiac toxicity and other cardiovascular risk factors. As others, 71 we argue that more evidence is needed supporting the different genetic markers before clinical guidelines for genetic testing for CTRCD susceptibility can be implemented. The generalizability of the studies that identified the 3 abovementioned markers, even in children, is questionable and the consequences of genotyping these SNPs in a diagnostic setting are uncertain. Furthermore, it is unclear what alterations in management should be made based on the results of the genetic testing and what the consequences of such management alterations are.
With well-constructed replication studies to validate true-positive findings and remove false-positive SNPs listed in this review and with the identification of additional SNPs in the future, clinical risk assessment could be expanded by genotyping these SNPs before the administration of chemotherapeutic regimens containing cardiotoxic agents, ideally in conjunction with the molecular characterization of the tumor. This approach may lead to the possibility of setting an individualized threshold of the maximum cumulative anthracycline dose where patients with a favorable genetic profile and low risk of CTRCD (Figure 2 ) might benefit from an increased cumulative dose with a larger antineoplastic effect. In contrast, patients with an unfavorable genetic profile may be better off with alterations in chemotherapeutic regimen in both dose and agent. Furthermore, this latter group will benefit from more frequent cardiac monitoring, facilitating early detection of cardiac compromise, and early treatment initiation once CTRCD has developed.
The European Society of Cardiology recently published a position paper with guidelines on cancer treatments and cardiovascular toxicity. 72 Cardioprotective drugs that have been tested and found potentially effective in a handful of cohorts are among others dexrazoxane, β-blockers, angiotensin antagonists, aldosterone antagonists, and statins. 73 Dexrazoxane was initially thought to mediate its cardioprotective because of iron chelation; however, recent research supports a model in which this agent depletes topoisomerase-2β levels. 74 Randomized controlled trials that presently are being conducted will hopefully lead to more robust evidence about the efficacy of chemical cardioprotection. 73 Clinical studies have in addition proven that once AIC has developed, treatment with angiotensin-converting enzyme inhibitors and β-blockers may be effective. 73 We consider the large variation in demographic composition between studies, the greatest limitation in the field, reducing the possibilities to draw firm conclusions from our findings or give recommendations on genetic testing in a clinical setting. Future homogenous designed studies that allow for mutual comparison are necessary to unravel the genetic basis of CTRCD. These efforts should include the validation A B Figure 2 . Relationship between genetic profile, incidence of cardiotoxicity, and tolerated cumulative anthracycline dose. A, The factors that influence the risk of developing chemotherapy-related cardiac dysfunction (CTRCD) can be subdivided into 3 large subgroups namely patient-related clinical risk factors, treatment-related risk factors of which cumulative anthracycline dose is the most important, and the individual genetic profile. With these 3 subgroups, the following model can be created. B, In this model, patients with an unfavorable genetic profile, leading to higher levels of reactive oxygen species (ROS) and topoisomerase-2β, increased accumulation of cardiotoxic anthracycline metabolites, and poorer sarcomere function, are more prone to develop CTRCD, even when treated with low anthracycline doses (indicated by the orange arrow). In the presence of other risk factors, the incidence of cardiotoxicity increases even further (red arrow). On the other hand, patients with a favorable genetic profile, leading to the protection against ROS, lower topoisomerase-2β levels, better clearance of cardiotoxic metabolites, and a stable sarcomere structure, tolerate higher doses of anthracyclines. However, in these patients, the combination of a high anthracycline dose in addition to the presence clinical risk factors also raises the risk of cardiotoxicity. of identified genetic variants in this review in larger and well-phenotyped cohorts. Furthermore, where GWAS has been a widespread approach to delineate genetic risk factors in complex common diseases such as diabetes mellitus, 75 only 5 studies have used this methodology in CTRCD. 13, 15, 31, 40, 76 The full potential of GWAS in CTRCD needs to be further ascertained and whole exome sequencing in patients with a disproportionate severe phenotype for rare variants with a large effect size. In addition, another promising research tool that recently has been established is the application of human-induced pluripotent stem cell-derived cardiomyocytes. 56 In a small pilot study, these cells were shown to predict doxorubicin-induced cardiotoxicity and, in addition, support current ruling theories on the pathophysiological mechanism of AIC that are discussed above. These and other studies are required to deepen our understanding of the pathophysiological mechanisms of CTRCD, which altogether may aid clinical risk assessment and thereby improve cardiovascular outcome.
CONCLUSIONS
As the life expectancy of cancer patients continues to improve, prevention and management of CTRCD will become increasingly important. Proper risk assessment remains challenging, as risk factors of this adverse drugs reaction are largely unknown. Although many identified polymorphisms in this review show potential to improve risk stratification (CELF4 rs1786814, RARG rs2229774, SLC28A3 rs7853758, UGT1A6 rs17863783) and 1 intergenic variant (rs28714259), future studies are needed to assess their value in a diagnostic and prognostic setting. 
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